Pavlu J, Apperley JF. Allogeneic SCT in chronic phase CML: who should you transplant? Myeloproliferative Disorders in practice 2009; 3.2: 3

Myeloproliferative Disorders in practice

Reference list

Pavlu J, Apperley JF. Allogeneic SCT in chronic phase CML: who should you transplant? Myeloproliferative Disorders in practice 2009; 3.2: 3–5.

1. Gratwohl A, Brand R, Apperley J et al. Allogeneic hematopoietic stem cell transplantation for chronic myeloid leukemia in Europe 2006: transplant activity, long-term data and current results. An analysis by the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation (EBMT). Haematologica 2006; 91: 513–521.

2. Gratwohl A, Hermans J, Goldman JM et al. Risk assessment for patients with chronic myeloid leukaemia before allogeneic blood or marrow transplantation. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation. Lancet 1998; 352: 1087–1092.

3. Pavlu J, Klammer M, Gabriel I et al. Allogeneic Myeloablative Hematopoietic Stem Cell Transplantation for Chronic Myelogenous Leukemia in the Imatinib Era. Blood (ASH Annual Meeting Abstracts) 2008; 112: Abstract 970.

4. Gilleece MH, Dazzi F. Donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukaemia. Leuk Lymphoma 2003; 44: 23–28.

5. Kolb HJ, Mittermuller J, Clemm C et al. Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood 1990; 76: 2462–2465.

6. Crawley C, Szydlo R, Lalancette M et al. Outcomes of reduced-intensity transplantation for chronic myeloid leukemia: an analysis of prognostic factors from the Chronic Leukemia Working Party of the EBMT. Blood 2005; 106: 2969–2976.

7. Olavarria E, Siddique S, Griffiths MJ et al. Posttransplantation imatinib as a strategy to postpone the requirement for immunotherapy in patients undergoing reduced-intensity allografts for chronic myeloid leukemia. Blood 2007; 110: 4614–4617.

8. Kantarjian HM, Smith TL, O'Brien S et al. Prolonged survival in chronic myelogenous leukemia after cytogenetic response to interferon-alpha therapy. The Leukemia Service. Ann Intern Med 1995; 122: 254–261.

9. de Lavallade H, Apperley JF, Khorashad JS et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 2008; 26: 3358–3363.

10. Druker BJ, Guilhot F, O'Brien SG et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006; 355: 2408–2417.

11. Baccarani M, Saglio G, Goldman J et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006; 108: 1809–1820.

12. Marin D, Milojkovic D, Olavarria E et al. European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor. Blood 2008; 112: 4437–4444.

13. Gratwohl A, Baldomero H, Schwendener A et al. Predictability of hematopoietic stem cell transplantation rates. Haematologica 2007; 92: 1679–1686.

14. Kantarjian HM, Giles F, Bhalla KN et al. Nilotinib in Chronic Myeloid Leukemia Patients in Chronic Phase (CMLCP) with Imatinib Resistance or Intolerance: 2-Year Follow-up Results of a Phase 2 Study. Blood (ASH Annual Meeting Abstracts) 2008; 112: Abstract 3238.

15. Shah NP, Kim D-W, Kantarjian HM et al. Dasatinib Dose-Optimization in Chronic Phase Chronic Myeloid Leukemia (CML-CP): Two-Year Data from CA180-034 Show Equivalent Long-Term Efficacy and Improved Safety with 100 Mg Once Daily Dose. Blood (ASH Annual Meeting Abstracts) 2008; 112: Abstract 3225.

16. Milojkovic D, Bua M, Apperley JF et al. Prediction of Cytogenetic Response to Second Generation TKI Therapy in CML Chronic Phase Patients Who Have Failed Imatinib Therapy and Early Identification of Factors That Influence Survival. Blood (ASH Annual Meeting Abstracts) 2008; 112: Abstract 332.

17. Tam CS, Kantarjian H, Garcia-Manero G et al. Failure to achieve a major cytogenetic response by 12 months defines inadequate response in patients receiving nilotinib or dasatinib as second or subsequent line therapy for chronic myeloid leukemia. Blood 2008; 112: 516–518.

18. Garg RnJ, Kantarjian HM, O'Brien S et al. The Use of 2nd generation Tyrosine Kinase Inhibitors (TKI) after Failure to 2 Prior TKI: Long-Term Follow-up. Blood (ASH Annual Meeting Abstracts) 2008; 112: Abstract 2119.

19. Beelen DW, Graeven U, Elmaagacli AH et al. Prolonged administration of interferon-alpha in patients with chronic-phase Philadelphia chromosome-positive chronic myelogenous leukemia before allogeneic bone marrow transplantation may adversely affect transplant outcome. Blood 1995; 85: 2981–2990.

20. Morton AJ, Gooley T, Hansen JA et al. Association between pretransplant interferon-alpha and outcome after unrelated donor marrow transplantation for chronic myelogenous leukemia in chronic phase. Blood 1998; 92: 394–401.

21. Bornhauser M, Kroger N, Schwerdtfeger R et al. Allogeneic haematopoietic cell transplantation for chronic myelogenous leukaemia in the era of imatinib: a retrospective multicentre study. Eur J Haematol 2006; 76: 9–17.

22. Deininger M, Schleuning M, Greinix H et al. The effect of prior exposure to imatinib on transplant-related mortality. Haematologica 2006; 91: 452–459.

23. Oehler VG, Gooley T, Snyder DS et al. The effects of imatinib mesylate treatment before allogeneic transplantation for chronic myeloid leukemia. Blood 2007; 109: 1782–1789.

24. Perz JB, Khorashad JS, Marin D, Apperley JF, Olavarria E. Imatinib preceding allogeneic stem cell transplantation in chronic myeloid leukemia. Haematologica 2006; 91: 1145–1146.

25. Shimoni A, Kroger N, Zander AR et al. Imatinib mesylate (STI571) in preparation for allogeneic hematopoietic stem cell transplantation and donor lymphocyte infusions in patients with Philadelphia-positive acute leukemias. Leukemia 2003; 17: 290–297.

26. Zaucha JM, Prejzner W, Giebel S et al. Imatinib therapy prior to myeloablative allogeneic stem cell transplantation. Bone Marrow Transplant 2005; 36: 417–424.

27. Lee SJ, Kukreja M, Wang T et al. Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia. Blood 2008; 112: 3500–3507.

Published by Hayward Medical Communications